Collegium Pharmaceutical (COLL) Profit After Tax (2014 - 2026)

Collegium Pharmaceutical's Profit After Tax history runs 13 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 499.75% year-over-year to $14.5 million; the TTM figure through Mar 2026 stood at $74.9 million (up 70.75% YoY), while the FY2025 annual figure was $62.9 million, down 9.13% from the prior year.
• Profit After Tax was $14.5 million for Q1 2026 at Collegium Pharmaceutical, down from $17.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $31.9 million in Q4 2023 to a low of -$17.4 million in Q1 2023.
• Historically, Profit After Tax has averaged $10.0 million across 5 years, with a median of $12.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax sank 183.44% in 2022, then jumped 4415.1% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$7.2 million in 2022, then soared by 543.67% to $31.9 million in 2023, then tumbled by 60.75% to $12.5 million in 2024, then surged by 35.31% to $17.0 million in 2025, then declined by 14.54% to $14.5 million in 2026.
• The last three Profit After Tax figures came in at $14.5 million (Q1 2026), $17.0 million (Q4 2025), and $31.5 million (Q3 2025), per Business Quant data.